Peter Stazzone's most recent trade in Lixte Biotechnology Holdings Inc was a trade of 50,000 Common Stock done . Disclosure was reported to the exchange on July 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lixte biotech Holdings Inc | Peter Stazzone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2026 | 50,000 | 100,000 | - | 0 | Common Stock | |
| Lixte biotech Holdings Inc | Peter Stazzone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2026 | 50,000 | 50,000 | - | - | Common Stock | |
| Lixte biotech Holdings Inc | Peter Stazzone | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Apr 2026 | 50,000 | 0 | - | - | Options to Purchase Common Stock | |
| Lixte biotech Holdings Inc | Peter Stazzone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2025 | 50,000 | 50,000 | - | - | Options to Purchase Common Stock |